1. INTRAVITREAL RITUXIMAB AS TREATMENT FOR INTRAOCULAR LYMPHOMA
Naon Kim
Karla P Gonzales Farro
Pablo Gili Manzanaro
Mª Carmen García Saénz.

2. CASE REPORT 56-year-old woman visual loss in her right eye
Personal history:
Breast B cell Non Hodgkin Lymphoma ( complete remission in 2011 with R-CHOP+ Radiotherapy)
Autoinmune Encephalitis with intracraneal space occupying lesions compatible with lymphoma ? (intracraneal biopsy- , cerebrospinal fluid -) Treated with metotrexate (2013)

3. Color funduscopy Visual acuity Right eye:0,2 Left eye:0,7
BMC: vitreous tyndall RE
Funduscopy: multiple yellow lesions
Color funduscopy

4. Green filter
Color
AGF
ICG

5. OCT Cirrus

6. CASE REPORT (cytology, flow cytometry)
Diagnostic 23G pars plana vitrectomy
No conclusive results
(cytology, flow cytometry)
Treatment:
No systemic treatment indicated since anatomic pathology was negative
Ocular treatment options:
Intravitreal Metotrexate
Intravitreal Rituximab(1 mg/0,1 mL) monthly x 4

7. After Rituximab
(1 mg/0,1 mL) monthly x 4

9. Visual acuity after
treatment
RE: 0,7

10. rituximab
CONCLUSIONS
Rituximab has been used for treating systemic lymphoma and other inflammatory conditions.
Eventhough the diagnosis of intraocular of lymphoma was not certain (AP -), intravitreal rituximab has brought excellent results.
Rituximab can be considered a good alternative for intraocular lymphoma treatment